Etude des mécanismes d’action de l’anticorps anti-CTLA4 et de leurs liens avec le microbiote intestinal
Le CTLA4 permet de maintenir la tolérance du soi et prévient le développement d’auto-immunités. Contenu au sein de vésicules intra-cytoplasmiques des lymphocytes T au repos, le CTLA4 est exprimé à la membrane plasmique suite à l’activation du TCR, on le qualifie de rétrocontrôle inhibiteur du systèm...
Main Author: | Vétizou, Marie |
---|---|
Other Authors: | Paris 11 |
Language: | fr |
Published: |
2015
|
Subjects: | |
Online Access: | http://www.theses.fr/2015PA11T035 |
Similar Items
-
CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade
by: Josselyn E. Garcia-Perez, et al.
Published: (2019-05-01) -
Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
by: Amirali Karimi, et al.
Published: (2021-03-01) -
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma
by: Emily Z. Keung, et al.
Published: (2018-09-01) -
Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
by: Ahmad Tarhini, et al.
Published: (2018-10-01) -
Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review
by: Rodolfo Chicas-Sett, et al.
Published: (2018-02-01)